Tritanrix-HepB
Infections, Streptococcal
GlaxoSmithKlinePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Infections, Streptococcal cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
POLIO SABIN GlaxoSmithKline | Phase 3 | BB |
gsk1024850a GlaxoSmithKline | Phase 3 | BB |
H INFLUENZAE B WHOLE GlaxoSmithKline | Phase 3 | BB |
Oritavancin Targanta Therapeutics Corporation | Phase 2 | B |
Ceftobiprole Basilea Pharmaceutica | Phase 1 | CC |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →